[go: up one dir, main page]

PE20180497A1 - Analogos de amilina - Google Patents

Analogos de amilina

Info

Publication number
PE20180497A1
PE20180497A1 PE2017001497A PE2017001497A PE20180497A1 PE 20180497 A1 PE20180497 A1 PE 20180497A1 PE 2017001497 A PE2017001497 A PE 2017001497A PE 2017001497 A PE2017001497 A PE 2017001497A PE 20180497 A1 PE20180497 A1 PE 20180497A1
Authority
PE
Peru
Prior art keywords
gly
lsstnvgsnt
lle
apr
refers
Prior art date
Application number
PE2017001497A
Other languages
English (en)
Inventor
Rasmus Just
Oliver Demmer
Lise Giehm
Jesper Sloth VILLADSEN
Henrik Kofoed Munch
Jolanta Skarbaliene
Maria Alexandrovna Deryabina
Dieter Wolfgang Hamprecht
Jesper Mosolff Mathiesen
Original Assignee
Zealand Pharma As
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180497(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma As, Boehringer Ingelheim Int filed Critical Zealand Pharma As
Publication of PE20180497A1 publication Critical patent/PE20180497A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)

Abstract

SE REFIERE A ANALOGOS DE AMILINA DE FORMULA R1-Z-R2, EN DONDE R1 ES H, ACILO C1-4, BENZOILO, ENTRE OTROS; R2 ES OH O NHR3, DONDE R3 ES H O ALQUILO C1-3; Z ES UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE: RCNTATCATQRLADFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP; RCNTATCATQRLADFLHRSSNNF-Gly(Me)-A-lle(Me)-LSSTNVGSNT-Apr; y RCNTATCATQRLAHFLHRSSNNF-Gly(Me)-A-lle(Me)-LSSTNVGSNT-Apr. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE OBESIDAD, DIABETES
PE2017001497A 2015-03-18 2016-03-17 Analogos de amilina PE20180497A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15159737 2015-03-18

Publications (1)

Publication Number Publication Date
PE20180497A1 true PE20180497A1 (es) 2018-03-09

Family

ID=52779493

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001497A PE20180497A1 (es) 2015-03-18 2016-03-17 Analogos de amilina

Country Status (19)

Country Link
US (2) US10766939B2 (es)
EP (1) EP3271381B1 (es)
JP (1) JP6769984B2 (es)
KR (1) KR20170126504A (es)
CN (1) CN107567459B (es)
AR (1) AR103954A1 (es)
AU (1) AU2016232218B2 (es)
BR (1) BR112017019378A2 (es)
CA (1) CA2979950A1 (es)
CL (1) CL2017002256A1 (es)
CO (1) CO2017008870A2 (es)
EA (1) EA035791B1 (es)
IL (1) IL253924A0 (es)
MX (1) MX2017011182A (es)
PE (1) PE20180497A1 (es)
PH (1) PH12017501674A1 (es)
SG (1) SG11201707286UA (es)
TW (1) TW201706294A (es)
WO (1) WO2016146739A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035791B1 (ru) 2015-03-18 2020-08-11 Зилэнд Фарма А/С Аналоги амилина
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
MX2021004185A (es) 2018-10-11 2021-09-08 Intarcia Therapeutics Inc Polipeptidos analogos de la amilina humana y sus metodos de uso.
JOP20220110A1 (ar) 2019-11-11 2023-01-30 Boehringer Ingelheim Int ناهضات مستقبل npy2
WO2021216586A1 (en) * 2020-04-20 2021-10-28 Intarcia Therapeutics, Inc. Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics
MX2023001532A (es) 2020-08-07 2023-03-08 Boehringer Ingelheim Int Agonistas del receptor npy2 solubles.
CN116322741A (zh) * 2020-09-24 2023-06-23 古布拉有限公司 具有改善的胰淀素受体(hAMY3R)效力的hAM15-52类似物
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
CN113893349B (zh) * 2021-12-13 2022-07-22 北京大学第三医院（北京大学第三临床医学院） 达格列净及其类似物在制备防治雄性生殖功能障碍的药物中的用途
KR20250017252A (ko) * 2022-05-27 2025-02-04 항저우 사이윈드 바이오사이언시즈 컴퍼니 리미티드 인간 아밀린 유사체 및 이의 유도체 및 이의 용도
TWI880227B (zh) * 2022-05-30 2025-04-11 丹麥商西蘭製藥公司 澱粉素類似物之液體調配物
WO2024022465A1 (zh) * 2022-07-29 2024-02-01 杭州九源基因工程有限公司 一种人胰淀素多肽衍生物及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
DK0567626T3 (da) * 1991-11-19 2001-12-17 Amylin Pharmaceuticals Inc Amylin-agonist-peptider og anvendelse deraf
AU7685894A (en) 1993-09-07 1995-03-27 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
US5677279A (en) 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO1999034764A2 (en) 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
BR0009040A (pt) 1999-03-17 2001-12-18 Novo Nordisk As Método para acilar um grupo amino de um peptìdeoou de uma proteìna, e, composto
WO2005000222A2 (en) 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
WO2006083254A1 (en) 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
DE102004051014A1 (de) 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
JP5252435B2 (ja) 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP2340261B1 (en) 2008-10-21 2017-12-20 Novo Nordisk A/S Amylin derivatives
EA020596B1 (ru) 2008-12-15 2014-12-30 Зилэнд Фарма А/С Аналоги глюкагона
US8685919B2 (en) 2008-12-15 2014-04-01 Zealand Pharma A/S Glucagon analogues
US8642541B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
AU2008365556A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
CN102639559B (zh) 2009-11-25 2015-04-29 诺沃—诺迪斯克有限公司 用于制备多肽的方法
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
KR20130086343A (ko) 2010-06-24 2013-08-01 질랜드 파마 에이/에스 글루카곤 유사체
ES2664509T3 (es) 2011-06-10 2018-04-19 Novo Nordisk A/S Derivados de pramlintida
SG11201403377QA (en) 2011-12-23 2014-07-30 Zealand Pharma As Glucagon analogues
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
WO2013156594A1 (en) * 2012-04-19 2013-10-24 Novo Nordisk A/S Human amylin analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
JP2016208556A (ja) * 2013-10-03 2016-12-08 三菱電機株式会社 デマンド予測装置及びデマンド予測方法
DK3137494T3 (da) 2014-05-02 2021-10-04 Univ New York State Res Found Isletamyloidpolypeptider med forbedret opløselighed
WO2016034604A1 (en) 2014-09-04 2016-03-10 Novo Nordisk A/S Novel amylin and calcitonin receptor agonist
EA035791B1 (ru) 2015-03-18 2020-08-11 Зилэнд Фарма А/С Аналоги амилина
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues

Also Published As

Publication number Publication date
EP3271381B1 (en) 2021-09-08
PH12017501674A1 (en) 2018-03-12
EA035791B1 (ru) 2020-08-11
BR112017019378A2 (pt) 2019-02-19
AR103954A1 (es) 2017-06-14
EP3271381A1 (en) 2018-01-24
US20210115104A1 (en) 2021-04-22
AU2016232218B2 (en) 2020-09-10
MX2017011182A (es) 2018-06-06
US10766939B2 (en) 2020-09-08
EA201791617A1 (ru) 2018-02-28
CN107567459B (zh) 2021-09-24
SG11201707286UA (en) 2017-10-30
AU2016232218A1 (en) 2017-09-21
KR20170126504A (ko) 2017-11-17
IL253924A0 (en) 2017-10-31
CO2017008870A2 (es) 2017-11-10
CN107567459A (zh) 2018-01-09
US20160272693A1 (en) 2016-09-22
JP2018510871A (ja) 2018-04-19
CL2017002256A1 (es) 2018-04-02
CA2979950A1 (en) 2016-09-22
WO2016146739A1 (en) 2016-09-22
JP6769984B2 (ja) 2020-10-14
TW201706294A (zh) 2017-02-16

Similar Documents

Publication Publication Date Title
PE20180497A1 (es) Analogos de amilina
PE20171322A1 (es) Dinucleotidos ciclicos utiles para el tratamiento del cancer entre otros
PE20150627A1 (es) Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
CL2016000873A1 (es) Analogos de glucagon acilado, una composicion que lo comprende; su uso para la fabricacion de un medicamento util para impedir el aumento de peso; un kit y un procedimiento.
PE20130281A1 (es) Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
BR112018006920A2 (pt) agonistas dos receptores de glucagon
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
EA201790024A1 (ru) Модуляторы toll-подобных рецепторов для лечения вич
PE20142098A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
BR112018075259A2 (pt) composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0
AR094966A1 (es) Composiciones farmacéuticas para el tratamiento de infecciones hcv
MX2016002368A (es) Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1).
PE20150224A1 (es) Inhibidores del nampt
ECSP18061667A (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
EA201400827A1 (ru) Материалы и способы лечения диареи
EA201700504A1 (ru) 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение
EA201400537A1 (ru) 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА
PE20171622A1 (es) Formulacion de relacion fija de insulina glargina/lixisenatida
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
CR20130501A (es) Derivados novedosos de cefalosporinas y composiciones farmacéuticas de estos
EA201790570A1 (ru) Модуляторы р2х7
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
ECSP13013075A (es) Método de tratamiento de la fiebre dengue